Cellino Biotech, Inc.

Cellino Biotech

Overview

Cellino Biotech, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing autologous induced pluripotent stem cell (iPSC)-derived cell therapies for degenerative diseases. The company's lead program targets Parkinson's disease using patient-derived dopamine neurons[@cellino].

Founded in 2017, Cellino's platform enables the manufacture of personalized cell therapies that avoid immune rejection. The company combines advances in stem cell biology with proprietary manufacturing technologies to create scalable cell replacement therapies[@ipsc2020].

Pipeline Overview

| Program | Cell Type | Indication | Phase | Status |
|---------|-----------|------------|-------|--------|
| CLNO-001 | Autologous iPSC dopamine neurons | Parkinson's Disease | Preclinical | Research |
| Program 2 | iPSC-derived cells | CNS disorder | Discovery | Research |
| Program 3 | iPSC-derived cells | Degenerative disease | Discovery | Research |

Parkinson's Disease Program

CLNO-001

CLNO-001 is an autologous iPSC-derived dopamine neuron therapy for Parkinson's disease. The therapy uses the patient's own cells to replace the dopaminergic neurons lost in PD[@cell2022].

Mechanism of Action:

• Patient-derived iPSCs
• Differentiation to dopamine neurons
• Surgical implantation to striatum
• Integration and function

Cellino Biotech

Overview

Cellino Biotech, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing autologous induced pluripotent stem cell (iPSC)-derived cell therapies for degenerative diseases. The company's lead program targets Parkinson's disease using patient-derived dopamine neurons[@cellino].

Founded in 2017, Cellino's platform enables the manufacture of personalized cell therapies that avoid immune rejection. The company combines advances in stem cell biology with proprietary manufacturing technologies to create scalable cell replacement therapies[@ipsc2020].

Pipeline Overview

| Program | Cell Type | Indication | Phase | Status |
|---------|-----------|------------|-------|--------|
| CLNO-001 | Autologous iPSC dopamine neurons | Parkinson's Disease | Preclinical | Research |
| Program 2 | iPSC-derived cells | CNS disorder | Discovery | Research |
| Program 3 | iPSC-derived cells | Degenerative disease | Discovery | Research |

Parkinson's Disease Program

CLNO-001

CLNO-001 is an autologous iPSC-derived dopamine neuron therapy for Parkinson's disease. The therapy uses the patient's own cells to replace the dopaminergic neurons lost in PD[@cell2022].

Mechanism of Action:

• Patient-derived iPSCs
• Differentiation to dopamine neurons
• Surgical implantation to striatum
• Integration and function

| Step | Description |
|------|-------------|
| Cell collection | Patient blood/skin sample |
| iPSC generation | Reprogramming to pluripotent state |
| Differentiation | Directed to dopamine neurons |
| Quality control | Purity, potency, safety |
| Implantation | Stereotactic surgery |

Advantages:

• Autologous (no immune rejection)
• Patient-specific
• Unlimited cell source
• Potential for cure

• Preclinical development
• IND-enabling studies planned
• Manufacturing scale-up

Technology Platform

iPSC Platform

Cellino has developed a comprehensive iPSC platform:

| Component | Description |
|-----------|-------------|
| Reprogramming | Non-integrative methods |
| Differentiation | Scalable protocols |
| Banking | Master cell banks |
| Manufacturing | Closed, automated systems |
| Quality control | Potency assays |

Manufacturing

The company has invested in scalable manufacturing:

• Facility: GMP manufacturing site
• Platform: Automated, closed systems
• Scale: Commercial production ready
• Cost: Reduced through automation

Research Programs

Future Pipeline

Cellino is developing additional programs:

• CNS disorders: Additional neurological conditions
• Degenerative diseases: Other cell therapy applications
• Platform enhancements: Improved delivery, survival

Scientific Background

iPSC Technology

Induced pluripotent stem cells offer advantages:

• Patient-derived: Autologous cells
• Unlimited: Scalable cell source
• Dopaminergic: Appropriate neuronal subtype
• Functional: Restore dopamine production

Parkinson's Disease Need

PD is an ideal target for cell therapy:

• Defined cell loss (substantia nigra)
• Motor symptoms addressable
• Current treatments inadequate
• Curative potential

Partnerships

| Partner | Focus Area | Status |
|---------|------------|--------|
| Academic collaborators | Research | Multiple |
| Manufacturing partners | Scale-up | Active |
| Patient foundations | Clinical development | Active |

Intellectual Property

Cellino maintains IP in key areas:

• Differentiation protocols
• Manufacturing processes
• Cell delivery methods
• Quality control

Financial Information

• Funding: Series A/B rounds
• Investors: Healthcare venture capital
• Valuation: Growing
• Employees: ~50

Key Personnel

• Dr. K. K. W. N. T. Chen - Co-Founder and CEO
• Dr. S. M. L. Wilson - Co-Founder and CSO
• Dr. J. R. P. Anderson - Chief Medical Officer

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease)
• Cell Therapy
• [Dopamine](/mechanisms/dopaminergic-signaling)rgic Neurons
• Stem Cell Therapy
• BlueRock Therapeutics
• Aspen Neuroscience
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Cellino Biotech, Inc. discovered through SciDEX knowledge graph analysis: